ABP 692

ocrelizumab · Amgen

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ABP 692, covering 2026-04-13 to 2026-06-09. Get the full timeline:

Most recent: Clinical Trial Update: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) [Phase 3]